Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis-Reference-Cited by-同舟云学术

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis

Published:2015-12-24 Issue:26 Volume:126 Page:2832-2841
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Blatt Katharina¹,Cerny-Reiterer Sabine¹²,Schwaab Juliana³,Sotlar Karl⁴,Eisenwort Gregor²,Stefanzl Gabriele¹,Hoermann Gregor⁵,Mayerhofer Matthias⁶,Schneeweiss Mathias¹⁷,Knapp Sylvia⁷⁸,Rülicke Thomas⁹,Hadzijusufovic Emir¹²¹⁰,Bauer Karin¹,Smiljkovic Dubravka¹,Willmann Michael¹⁰,Reiter Andreas³,Horny Hans-Peter⁴,Valent Peter¹²

Affiliation:

1. Department of Internal Medicine I, Division of Hematology and Hemostaseology and

2. Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria;

3. Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany;

4. Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany;

5. Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria;

6. Department of Laboratory Medicine, Hanusch Hospital, Vienna, Austria;

7. Department of Internal Medicine I, Laboratory of Infection Biology, Medical University of Vienna, Vienna, Austria;

8. Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria; and

9. Institute of Laboratory Animal Science and

10. Department/Clinic for Companion Animals and Horses, Clinic for Small Animals, Clinical Unit of Internal Medicine, University of Veterinary Medicine, Vienna, Austria

Abstract

Key Points In a majority of patients with advanced SM, neoplastic MCs express the target receptor CD30. The CD30-targeting drug brentuximab-vedotin blocks growth and survival in CD30+ neoplastic MCs which favors drug development in advanced SM.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/26/2832/1390935/2832.pdf

Reference58 articles.

1. Mastocytosis: current concepts in diagnosis and treatment.;Escribano;Ann Hematol,2002

2. Diagnosis and treatment of systemic mastocytosis: state of the art.;Valent;Br J Haematol,2003

3. Systemic mastocytosis.;Akin;Annu Rev Med,2004

4. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.;Valent;J Allergy Clin Immunol,2004

5. Mast cells and mastocytosis.;Metcalfe;Blood,2008

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcellular expression of CD30 in cutaneous mastocytosis—An important factor for targeted treatment;Journal of Cutaneous Pathology;2024-08-02

2. Nouveaux critères diagnostiques des mastocytoses : des progrès mais encore des interrogations;Bulletin de l'Académie Nationale de Médecine;2024-06

3. Histological characterization of liver involvement in systemic mastocytosis;Liver International;2024-03-30

4. Review and Updates on Systemic Mastocytosis and Related Entities;Cancers;2023-11-28

5. World Health Organization Classification and Diagnosis of Mastocytosis;Immunology and Allergy Clinics of North America;2023-11